http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Sang Ah,Cho, Suk Ju,Jeong, Myung Ho,Kim, Young Jo,Kim, Chong Jin,Cho, Myeong Chan,Kim, Hyo-Soo,Ahn, Youngkeun,Koh, Gwanpyo,Lee, Jeong mi,Oh, Seok Kyu,Yun, Kyeong Ho,Kim, Ha Young,Cho, Chung Gu,Le American Diabetes Association 2014 Diabetes Care Vol.37 No.8
<P><B>OBJECTIVE</B></P><P>We aimed to evaluate the association between hypoglycemia at admission and 30-day mortality in patients with acute myocardial infarction (AMI) and to determine whether these associations differed according to diabetes-control status in AMI patients with diabetes.</P><P><B>RESEARCH DESIGN AND METHODS</B></P><P>We analyzed the prognostic significance of hypoglycemia and hyperglycemia in 34,943 AMI patients with or without type 2 diabetes from two AMI registries: the Korea Acute Myocardial Infarction Registry (KAMIR) and the Korea Working Group on Myocardial Infarction (KorMI).</P><P><B>RESULTS</B></P><P>The patients were divided into five groups according to serum-glucose levels at admission: <3.9 mmol/L (<70 mg/dL); 3.9–7.72 mmol/L (70–139 mg/dL); 7.78–11.06 mmol/L (140–199 mg/dL); 11.11–14.39 mmol/L (200–259 mg/dL); and ≥14.44 mmol/L (≥260 mg/dL). The 30-day mortality rates in the lowest and highest glucose groups were higher than those in other groups; the lowest glucose group had the highest mortality for patients with type 2 diabetes, after adjusting for multiple factors. We also extracted and compared four subgroups from the patients with type 2 diabetes, based on hemoglobin A1c and serum-glucose levels at admission: group A, <6.5% (48 mmol/mol) and <3.9 mmol/L; group B, <6.5% (48 mmol/mol) and ≥11.11 mmol/L; group C, ≥8% (64 mmol/mol) and <3.9 mmol/L; and group D, ≥8% (64 mmol/mol) and ≥11.11 mmol/L. Group C had the highest 30-day mortality rate among the groups.</P><P><B>CONCLUSIONS</B></P><P>These data suggest that hypoglycemia at admission affects clinical outcomes differently in AMI patients with type 2 diabetes depending on the diabetes-control status.</P>
Lee, Youngkeun,Yoo, Soyeon,Kang, Seungyoon,Hong, Sukwon,Han, Min Su The Royal Society of Chemistry 2018 The Analyst Vol.143 No.8
<P>The development of artificial peroxidases has attracted great interest because of their applications in various fields such as the chemical industry and biosensing. In this study, 2,6-bis[(bis(2-pyridylmethyl)amino)-methyl]-4-methylphenol (H-bpmp) complexes with various transition metal ions have been investigated as artificial peroxidases. Among these metal complexes, the [Mn2(bpmp)]<SUP>3+</SUP> complex showed the highest peroxidase-like activity as determined by a colorimetric assay using 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and H2O2. The peroxidase-like activity was inhibited by pyrophosphate (PPi), which blocked the active site of the [Mn2(bpmp)]<SUP>3+</SUP> complex. Based on this phenomenon, the ABTS/H2O2/[Mn2(bpmp)]<SUP>3+</SUP> system could be applied for the detection of PPi, which could be achieved selectively by visual observation with a detection limit of 130 nM. Moreover, the addition of pyrophosphatase (PPase) to the [Mn2(bpmp)]<SUP>3+</SUP> complex blocked by PPi resulted in the recovery of the peroxidase-like activity of the [Mn2(bpmp)]<SUP>3+</SUP> complex due to the hydrolysis of PPi. Hence, the enzyme cascade reaction of the PPase and [Mn2(bpmp)]<SUP>3+</SUP> complex allowed the real-time colorimetric assay of PPase.</P>
( Jiyoung Lee ),( Youngkeun Ahn ),( Myung Ho Jeong ),( Dae Ho Lee ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Background: The benefit of statin therapy in patient with higher grades of heart failure has yet to be determined. The present study was performed to investigate whether statin therapy affects major clinical outcomes in patients with acute myocardial infarction (AMI) and heart failure within 1 year after AMI Methods: A total of 11,592 patients with AMI from a nationwide registry database in Korea were analyzed. The patients who had a natriuretic peptide (NP) measured at admission were categorized into quartiles by plasma level of B-type NP (BNP) or N-terminal pro-B-type NP (NT-proBNP). In a separate analysis, selected patients with left ventricular ejection fraction (LVEF) <40% on initial and/or follow-up echocardiography were evaluated. Major adverse cardiovascular events (MACEs) within 12 months of AMI, including death, nonfatal MI, and revascularization, were assessed, after adjusting for multiple factors. Results: Among 11,592 AMI patients, statin therapy was included in their medication at least from the hospital discharge in 9149 (78.9%) patients, whereas not in the remaining 2443 patients (21.1%), with statin therapy being associated with 24.2% lower risk of MACEs. After adjusting for risk factors, statin therapy was associated with significantly lower the hazard ratios (HRs) for MACEs only in the third and fourth quartiles of plasma NP level. However, statin did not modify the incidence of MACEs in patients with LVEF less than 40%. Conclusions: Our results show that statin therapy decreased the risk of MACEs in AMI patients with higher plasma natriuretic peptide, but not in patients with severe heart failure.
눈 특징점 탐지 기반의 실시간 시선 추적 방법에 관한 연구
이영근(Youngkeun Lee),김준식(Junsik Kim),유지상(Jisang Yoo),권순철(Soonchul Kwon) 한국통신학회 2021 한국통신학회 학술대회논문집 Vol.2021 No.6
본 논문은 눈 특징점을 탐지하고 탐지된 특징점들을 기반으로 하여 실시간으로 시선을 추적하는 방법을 제안한다. 본 연구는 특징점 추출에 특화된 인공 신경망과 서포트 벡터 회귀를 사용하여 정확하고 효율적으로 눈 특징점을 탐지하고 시선 벡터를 예측한다. 또한, 데이터 증강을 위한 합성 눈 이미지 데이터셋 구축 및 전처리 과정과 EAR 도입을 통한 오탐 감소를 활용하여 약 2.69°의 피치 오차, 약 2.21°의 요 오차의 성능을 보인다.
Ahn, Youngkeun,Kim, Yongcheol,Chang, Kiyuk,Kim, Weon,Rhee, Moo-Yong,Cha, Kwang Soo,Hyon, Min Su,Shim, Chi Young,Lee, Sung Yun,Kim, Doo Il,Kim, Sang Wook,Lim, Sang-Wook,Han, Kyoo-Rok,Jo, Sang-Ho,Lee, N Williams & Wilkins Co 2018 Medicine Vol.97 No.37
<P><B>Abstract</B></P><P><B>Background:</B></P><P>To determine whether the effectiveness and safety of fixed-dose combinations (FDCs) of amlodipine orotate/valsartan (AML/VAL) 5/160 mg are noninferior to those of valsartan/hydrochlorothiazide (VAL/HCTZ) 160/12.5 mg in hypertensive patients with inadequate response to valsartan 160 mg monotherapy.</P><P><B>Methods:</B></P><P>This 8-week, active-controlled, parallel-group, fixed-dose, multicenter, double-blind randomized controlled, and noninferiority trial was conducted at 17 cardiovascular centers in the Republic of Korea. Eligible patients had mean sitting diastolic blood pressure (msDBP) ≥90 mm Hg despite monotherapy with valsartan 160 mg for 4 weeks. Patients were randomly assigned to treatment with AML/VAL 5/160 mg FDC (AML/VAL) group or VAL/HCTZ 160/12.5 mg FDC (VAL/HCTZ) group once daily for 8 weeks. A total of 238 patients were enrolled (AML/VAL group, n = 121; VAL/HCTZ group, n = 117), of whom 228 completed the study.</P><P><B>Results:</B></P><P>At 8 weeks after randomization, msDBP was significantly decreased in both groups (−9.44 ± 0.69 mm Hg in the AML/VAL group and −7.47 ± 0.71 mm Hg in the VAL/HCTZ group, both <I>P</I> < .001 vs baseline). Between group difference was −1.96 ± 1.00 mm Hg, indicating that AML/VAL 5/160 mg FDC was not inferior to VAL/HCTZ 160/12.5 mg FDC at primary efficacy endpoint. Control rate of BP defined as the percentage of patients achieving mean sitting SBP (msSBP) <140 mm Hg or msDBP <90 mm Hg (target BP) from baseline to week 8 was significantly higher in the AML/VAL group than that in the VAL/HCTZ group (84.3% [n = 102] in the AML/VAL group vs 71.3% [n = 82] in the VAL/HCTZ group, <I>P</I> = .016). At 8 weeks after randomization, mean uric acid level was significantly increased in the VAL/HCTZ group compared to that at baseline (0.64 ± 0.08 mg/dL; <I>P</I> < .001). However, it was slightly decreased from baseline in the AML/VAL group (−0.12 ± 0.08 mg/dL; <I>P</I> = .085). The intergroup difference was significant (<I>P</I> < .001).</P><P><B>Conclusion:</B></P><P>The effectiveness and safety AML/VAL 5/160 mg FDC are noninferior to those of VAL/HCTZ 160/12.5 mg FDC in patients with hypertension inadequately controlled by valsartan 160 mg monotherapy.</P>
Ki Hong Lee,Jeong Gwan Cho,Nuri Lee,조경훈,Hyung Ki Jeong,Hyukjin Park,Yongcheol Kim,Jae Yeong Cho,김민철,Doo Sun Sim,Hyun Ju Yoon,Nam Sik Yoon,Kye Hun Kim,Young Joon Hong,Hyung Wook Park,Youngkeun Ahn,Myun 대한심장학회 2020 Korean Circulation Journal Vol.50 No.2
Background and Objectives: Although anticoagulation with warfarin is recommended as an international normalized ratio (INR) of prothrombin time between 2.0 and 3.0 and mean time in the therapeutic range (TTR) ≥70%, little has been proven that universal criteria might be suitable in Korean atrial fibrillation (AF) patients. Methods: We analyzed 710 patients with non-valvular AF who took warfarin. INR value and clinical outcomes were assessed during 2-year follow-up. Intensity of anticoagulation was assessed as mean INR value and TTR according to target INR range. Primary net-clinical outcome was defined as the composite of new-onset stroke and major bleeding. Secondary net-clinical outcome was defined as the composite of new-onset stroke, major bleeding and death. Results: Thromboembolism was significantly decreased when mean INR was over 1.6. Major bleeding was significantly decreased when TTR was over 70% and mean INR was less than 2.6. Mean INR 1.6–2.6 significantly reduced thromboembolism (adjusted hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.19–0.85), major bleeding (HR, 0.43; 95% CI, 0.23–0.81), primary (HR, 0.50; 95% CI, 0.29–0.84) and secondary (HR, 0.45; 95% CI, 0.28–0.74) net-clinical outcomes, whereas mean INR 2.0–3.0 did not. Simultaneous satisfaction of mean INR 1.6–2.6 and TTR ≥70% was associated with significant risk reduction of major bleeding, primary and secondary net-clinical outcomes. Conclusions: Mean INR 1.6–2.6 was better than mean INR 2.0–3.0 for the prevention of thromboembolism and major bleeding. However, INR 1.6–2.6 and TTR ≥70% had similar clinical outcomes to INR 2.0–3.0 and TTR ≥70% in Korean patients with non-valvular AF.
공공기관 기업부설연구소의 현주소 및 활성화 방안: 가스연구원을 중심으로
이승호(Seungho Lee),김영근(YoungKeun Kim),김동민(Dong-Min Kim),유정수(Jungsoo yoo),이영석(Young Suk Lee),조영아(Youngah Cho) 한국기술혁신학회 2019 한국기술혁신학회 학술대회 발표논문집 Vol.2019 No.11
In Korea, the Corporate Research Institute exists as a branch of public research institution. Such facilities, including the gas research institute, are currently struggling in financial and human resource as they are unable to secure investments comparable to that of private corporations. The inherent limit of most institutions stems from their tendency to maintain small-scale teams, thus making it all the more difficult to engage in more challenging research. In order to overcome such obstacles, Gas research institute have made various attempts to revolutionize R&D innovation. Improvement measures for the organization, human Resource management, and R&D processes have been reviewed, and efforts are being made to vitalize researchers. Open innovation is enlarged, decisions are made, and intensive strategies are implemented to promote new-growth. However, many research programs lack supporting staff resulting in decreased immersion in its studies. This results in overlapping research inside the agency. Small scale dispersion research also decreases the synergy effect among the group. The special law for national R&D innovation includes the improvement of government-funded research institutes and universities, but the laboratories of public institutions are in blind spots. As part of overcoming these limitations, the integrated operation plan of corporate R&D institutions of public gas and petroleum energy sector was reviewed.